Blue Note Therapeutics Enters Licensing Agreement With University of Sydney for ConquerFear, a Cancer Survivorship Intervention
03 févr. 2022 09h00 HE
|
Blue Note Therapeutics
SAN FRANCISCO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced...